Ballentine Partners LLC Sells 10,707 Shares of Organon & Co. $OGN

Ballentine Partners LLC decreased its position in Organon & Co. (NYSE:OGN) by 51.1% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 10,228 shares of the company’s stock after selling 10,707 shares during the period. Ballentine Partners LLC’s holdings in Organon & Co. were worth $99,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Ransom Advisory Ltd acquired a new position in shares of Organon & Co. during the 1st quarter worth approximately $32,000. Brooklyn Investment Group increased its position in shares of Organon & Co. by 1,012.3% during the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock worth $46,000 after purchasing an additional 2,794 shares during the last quarter. Ridgewood Investments LLC bought a new position in shares of Organon & Co. during the 2nd quarter worth approximately $48,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Organon & Co. during the 1st quarter worth approximately $51,000. Finally, GAMMA Investing LLC boosted its stake in shares of Organon & Co. by 22.4% during the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock worth $55,000 after acquiring an additional 1,034 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $10.68 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.15. The stock has a 50 day moving average of $9.81 and a 200-day moving average of $10.47. The company has a market capitalization of $2.78 billion, a P/E ratio of 3.97, a P/E/G ratio of 0.94 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last issued its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Organon & Co.’s dividend payout ratio is presently 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.